Monoclonal Antibodies in Neurology: Current State and Future Development

Monoclonal antibodies are one of the fastest growing areas of specific therapy for cancer, infectious, autoimmune, and demyelinating diseases. The main targets of monoclonal antibodies in autoimmune and demyelinating diseases are T and B lymphocytes, cytokines, complement, and adhesion molecules. In...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human physiology Jg. 48; H. 8; S. 932 - 937
1. Verfasser: Zakharova, M. N.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Moscow Pleiades Publishing 01.12.2022
Springer Nature B.V
Schlagworte:
Alzheimer's disease
Autoimmune diseases
Biomedical and Life Sciences
Biomedicine
CD19 antigen
CD20 antigen
Demyelinating diseases
Demyelination
Human Physiology
Life Sciences
Lymphocytes B
Monoclonal antibodies
Multiple sclerosis
Nanobodies
Neurodegenerative diseases
Neuromyelitis
Parenchyma
β-Amyloid
nanobodies
Alzheimer’s disease
demyelinating diseases
multiple sclerosis
neuromyelitis optica
monoclonal antibodies
ISSN:0362-1197, 1608-3164
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Monoclonal antibodies are one of the fastest growing areas of specific therapy for cancer, infectious, autoimmune, and demyelinating diseases. The main targets of monoclonal antibodies in autoimmune and demyelinating diseases are T and B lymphocytes, cytokines, complement, and adhesion molecules. In the field of neurodegenerative diseases, the largest number of studies has been carried out in patients with Alzheimer’s disease, in which the target for monoclonal antibodies is pathologically altered beta-amyloid protein that accumulates in the brain parenchyma. This review presents new therapeutic approaches to the use of antibody fragments, with an emphasis on their new class, nanobodies. Special attention is paid to new anti-CD20 and anti-CD19 monoclonal antibody drugs in multiple sclerosis (ocrelizumab, ofatumumab) and neuromyelitis optica (inebilizumab). Ocrelizumab is the first medication that proved to be effective in primary progressive multiple sclerosis. There have been significant advances in the treatment of neuromyelitis optica: the first multicenter study of Inebilizumab (MEDI-551) is currently underway.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:0362-1197
1608-3164
DOI:10.1134/S0362119722080072